Generex Biotechnology News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

16.01.19	Generex Biotechnology Announces Investor Conference Call Agenda Wednesday, January 16, at 4:00 p.m. Eastern (Businesswire)
11.01.19	Generex Biotechnology Subsidiary Olaregen Therapeutix Inc. Plans Launch of FDA Cleared Excellagen® Wound Conforming Gel Matrix with Three Dosage Options (Businesswire)
10.01.19	Generex Biotechnology Announces Acquisition of Surgical Supply and Distribution Company (Businesswire)
10.01.19	Generex Biotechnology Announces Investor Conference Call; Management to Provide Update on Acquisitions, Financing Initiatives & Strategic Plans (Businesswire)
09.01.19	Generex Biotechnology Announces Acquisition of Surgical Device Manufacturer (Businesswire)
08.01.19	Generex Biotechnology Completes Acquisition of Olaregen Therapeutix Inc. (Businesswire)
08.01.19	Generex Biotechnology Announces the Launch of a New Corporate Website (Businesswire)
07.01.19	Generex Biotechnology Completes Acquisition of Regentys Corporation (Businesswire)
07.01.19	Generex Biotechnology CEO Joe Moscato Attending J.P. Morgan Healthcare Conference (Businesswire)
04.01.19	Generex Biotechnology Provides Update on NuGenerex Immuno-Oncology (Businesswire)
03.01.19	Generex Biotechnology Partner Olaregen Therapeutix Inc. Signs Manufacturing Agreements for Excellagen® Wound Healing Collagen Matrix (Businesswire)
20.12.18	Generex Biotechnology Partner Olaregen Therapeutix Inc. Establishes Sales Force and Distribution Team for the Commercial Launch of Excellagen (Businesswire)
14.12.18	Generex Biotechnology Partner Regentys Corporation Receives European Patent Approval for ECMH™ for Treatment of Ulcerative Colitis (Businesswire)
13.12.18	Generex Biotechnology Partner Olaregen Therapeutix Sponsors Annual Meeting of Innovations in Wound Healing (Businesswire)
12.12.18	Generex Biotechnology Receives IND Approval from FDA for Phase II Combination Study using AE37 plus Keytruda® (pembrolizumab) for the Treatment of Triple Negative Breast Cancer (Businesswire)
10.12.18	Generex Provides Stock Market Alert (Businesswire)
04.12.18	Generex Posts Slides, Script & Recording of Investor Conference Call (Businesswire)
03.12.18	Generex Announces Acquisition of 100% of Hema Diagnostic Systems, Debt Restructuring & Warrant Deal (Businesswire)
30.11.18	Generex Announces Investor Conference Call-in Details; Management to Provide Update on Initiatives & Strategic Plans (Businesswire)
29.11.18	Generex Biotechnology Expands Medical Device & Wound Care Portfolio with Acquisition of Regentys Corporation (Businesswire)
28.11.18	Generex Biotechnology Adds World-Class Leadership to Executive Management Team (Businesswire)
28.11.18	Generex Biotechnology Expands Medical Device Portfolio with Acquisition of Olaregen Therapeutix Inc. (Businesswire)
26.11.18	Generex Announces NuGenerex HydroHealth CBD High Alkaline Health Water As First Target Product In Planned Line Of CBD Therapies (Businesswire)
21.11.18	Generex Provides Stock Market Alert (Businesswire)
16.11.18	Generex Announces Investor Conference Call; Management to Provide Update on Initiatives & Strategic Plans (Businesswire)
15.11.18	Generex Announces Appointment of Executive Management Team (Businesswire)
14.11.18	Generex Revises Record & Payment Dates for 20:1 Stock Dividend (Businesswire)
13.11.18	Generex Publishes Update to Pending 20:1 Stock Dividend (Businesswire)
07.11.18	Generex Addresses the Opioid Crisis; Provides Proven, Non-Opioid Pain Management Solutions (Businesswire)
05.11.18	Generex Announces REVISED Record & Payment Dates for 20:1 Stock Dividend (Businesswire)
02.11.18	Generex Biotechnology Finalizes Acquisition of Remaining Veneto Operating Assets (Businesswire)
31.10.18	Generex Biotechnology Announces Record & Payment Dates for 20:1 Stock Dividend (Businesswire)
29.10.18	Generex Biotechnology Announces IND Filing for a Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (Keytruda®) for the Treatment of Triple-Negative Breast Cancer (Businesswire)
22.10.18	Generex Confirms & Clarifies 20:1 Common Stock Dividend (Businesswire)
12.10.18	Generex Announces Anthony S. Crisci, Esq., CPA as General Manager, Chief Compliance Officer and Corporate Counsel of its New, Wholly-Owned Subsidiary, NuGenerex Distribution Solutions (Businesswire)
10.10.18	Generex Announces Stock Dividend (Businesswire)
09.10.18	Generex Announces Closing of First Tranche Acquisition of Operating Assets (Businesswire)
05.10.18	Generex Biotechnology Provides Update on AE37 Immuno-Therapeutic Clinical Development Program (Businesswire)
04.10.18	Generex Biotechnology Corporation Shareholder Alert (Businesswire)
26.09.18	Generex Launches NuGenerex Medical Marketing (Businesswire)
20.09.18	Generex Subsidiary Hema Diagnostic Systems, LLC dba NuGenerex Diagnostics Announces Filing of a European CE Marking Application (Businesswire)
27.08.18	Generex Biotechnology to Present Overview of Immuno-Oncology Development Program at Summit in Boston, MA (Businesswire)
02.07.18	Generex Biotechnology Corporation Announces the Filing of a Patent for its New Diagnostic Point-of-Care Platform, the Express II (Businesswire)
25.06.18	Generex Announces Terry Thompson as Chief Operating Officer (Businesswire)
14.05.18	Cognito promotes Vivienne Hsu to International Managing Director (PR Newswire)
16.04.18	Kroton Educacional Presentation Now Available for On-Demand Viewing (PR Newswire)
11.04.18	AppBus named "Exponential" Innovator to Watch by ITL (PR Newswire)
04.01.18	Generex CEO Provides 2017 Year-End Summary to Stakeholders (Businesswire)
03.01.18	Generex Provides Access Information for Investor Conference Call Scheduled for January 4, 2018 (Businesswire)
03.01.18	Generex Announces Initial Pharmacy Acquisitions & Plans for Broader Acquisitions Strategy (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Lonza Grp	608.60	1.84 %	K V
CieFinRichemont	176.10	0.20 %	K V
Part Grp Hldg	1’380.00	0.07 %	K V
Zurich Insur Gr	553.60	0.07 %	K V
Logitech Intl	88.64	0.02 %	K V
Swisscom	506.50	-0.69 %	K V
Kuehne+Nagel Int	201.80	-0.69 %	K V
Nestle	77.30	-0.72 %	K V
Sonova Hldg	308.90	-2.25 %	K V
UBS Group	29.90	-5.95 %	K V

Nachrichten zu Generex Biotechnology Corp.

Aktien Top/Flop

Meistgelesene Nachrichten